enVVeno Medical Corporati... (NVNO)
| Bid | 0.75 |
| Market Cap | 15.59M |
| Revenue (ttm) | 812K |
| Net Income (ttm) | -23.07M |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -0.67 |
| Forward PE | -0.74 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.84 |
| Volume | 144,061 |
| Avg. Volume (20D) | 980,592 |
| Open | 0.78 |
| Previous Close | 0.78 |
| Day's Range | 0.77 - 0.82 |
| 52-Week Range | 0.67 - 5.62 |
| Beta | 0.94 |
| Ex-Dividend Date | n/a |
About NVNO
undefined
2 weeks ago · accessnewswire.com
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" SegmentWatch the "What This Means" video here IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of ca...
1 month ago · accessnewswire.com
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous diseas...
2 months ago · accessnewswire.com
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech- Live webcast on Thursday, August 21stat 2:00 PM ET IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new stan...
2 months ago · accessnewswire.com
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readine...
